Clinical trials: Stage IV, NSCLC
Non-small Cell Lung Cancer Stage IIIB/IV
Oral Chemotherapeutic Drugs Were Analyzed in Patients With Driver Gene Negative Locally Advanced/Advanced Non-small Cell Lung Cancer With PS Score 2 A Prospective, Single-arm, Multicenter, Observational Study on the Efficacy and Safety of Radiochemotherapy Combined With PD-1 Inhibitor
Oral chemotherapeutic drugs were analyzed in patients with driver gene negative locally advanced/advanced non-small cell lung cancer with PS score 2 A prospective, single-arm, multicenter, observational study on the efficacy and…
- Trial name
- NCT06310915
- Testing
- Navelbine oral,Pembrolizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Colon Cancer Metastatic, Head and Neck Cancer Metastatic
A Study of ADXS-NEO Expressing Personalized Tumor Antigens
This is a Phase 1, open-label, multicenter study of ADXS-NEO administered alone and in combination with pembrolizumab in participants with select advanced or metastatic solid tumors.
- Conditions
- Colon Cancer Metastatic, Head and Neck Cancer Metastatic, Metastatic Non-Small Cell Lung Cancer, Urothelial Carcinoma
- Trial name
- NEO (NCT03265080)
- Testing
- ADXS-NEO, Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 13 people
- Sponsor
- Advaxis, Inc.
Exercise, Neoplasms
Monitoring and Telecoaching of Physical Activity in Patients With Stage III and IV Non-small Cell Lung Cancer
This study is a prospective non-randomised control study to evaluate the efficacy of a physical activity promotion program on the experience of physical activity in patients with stage III and IV non-small cell lung cancer…
- Trial name
- NCT03883243
- Testing
- Telecoaching
- Where
- Belgium
- Volunteers
- 32 people
- Sponsor
- KU Leuven
Lung Non-Small Cell Carcinoma
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer.
- Trial name
- NCT06116682
- Testing
- Amivantamab, Biospecimen Collection, Computed Tomography
- Where
- 271 sites in United States
- Volunteers
- 88 people
- Sponsor
- SWOG Cancer Research Network
Squamous Non-Small Cell Lung Cancer
A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology
A multi-center Phase Ib/II study of the combination of RO5479599 with carboplatin and paclitaxel once in every 3 week (q3w) regimen to evaluate the safety and tolerability.
- Trial name
- NCT02204345
- Testing
- Carboplatin, Paclitaxel, RO5479599
- Where
- 6 sites in Canada, Denmark and 1 more
- Volunteers
- 12 people
- Sponsor
- Hoffmann-La Roche
Non-small Cell Lung Cancer (NSCLC)
A Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non-small Cell Lung Cancer (NSCLC)
This single arm study will assess the safety and efficacy of Endostar combined with chemotherapy (Gemcitabine plus Platinum-based chemotherapy) followed by Endostar maintenance therapy in patients with stage IIIB/IV non-small…
- Trial name
- NSCLC (NCT01028729)
- Testing
- Endostar, Gemcitabine-Cisplatin chemotherapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Simcere Pharmaceutical Co., Ltd
Non-small Cell Lung Cancer
A Clinical Study on the Safety and Efficacy of Debio 0932 in Combination With Standard of Care in Patients With Non-small Cell Lung Cancer [NSCLC]
Part A of this study will investigate the Maximum Tolerated Dose of Debio 0932 in combination with standard of care chemotherapy for the first- and second-line treatment of advanced NSCLC.
- Trial name
- HALO (NCT01714037)
- Testing
- Debio 0932, Cisplatin, Pemetrexed
- Where
- 8 sites in France, Spain and 1 more
- Volunteers
- 82 people
- Sponsor
- Debiopharm International SA
Non-Small Cell Carcinoma of Lung, TNM Stage 4
A Real World Study Based on NGS (TRUMPRWS)
This is a descriptive observational study, in which data are collected in an epidemiological fashion. This study does not intend to alter or intervene the current medical practice of the recruited patients.
- Trial name
- TRUMPRWS (NCT03605602)
- Testing
- No treatment is included in this protocol.
- Where
- China
- Volunteers
- 2,700 people
- Sponsor
- Guangdong Association of Clinical Trials
Non-Small Cell Lung Cancer, Lung Cancer, Cancer
Disease Characteristics, Treatment Patterns and Clinical Outcomes in Patients With Newly Diagnosed Unresectable Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) in China
The purpose of this observational study is to describe patient and disease characteristics as well as treatment patterns in Chinese patients with unresectable stage IIIB or IV non-small cell lung cancer (NSCLC).
- Trial name
- NCT02458651
- Testing
- No intervention
- Where
- 11 sites in China
- Volunteers
- 1,378 people
- Sponsor
- Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
The purpose of this study is to compare pembrolizumab (MK-3475) in combination with sacituzumab govitecan with pembrolizumab alone with respect to progression-free survival (PFS) and overall survival (OS) per Response Evaluation…
- Trial name
- NCT05609968
- Testing
- Sacituzumab Govitecan, Pembrolizumab
- Where
- 180 sites in United States, Australia and 23 more
- Volunteers
- 614 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Small Cell Lung Carcinoma (NSCLC)
ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung Cancer
The purpose of this study is to determine the safety and effectiveness of Iressa when used with a short course of high dose radiation therapy in patients with lung cancer.
- Trial name
- NCT00328562
- Testing
- ZD1839 (Iressa), Thoracic Radiotherapy
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NSCLC, PD-1
LM-108 Antibody Combination With Sintilimab for Locally Advanced or Metastatic Non-Small Cell Lung Cancer
The goal of this clinical trial is to investigate the efficacy, safety and tolerability of LM-108 antibody in combination with sintilimab for patients with locally advanced or metastatic Non-Small Cell Lung Cancer patients.
- Trial name
- ACCLAIM (NCT06479759)
- Testing
- LM-108 antibody and sintilimab, LM-108 antibody and sintilimab and chemotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer
Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways.
- Conditions
- Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer
- Trial name
- NCT00021060
- Testing
- paclitaxel, carboplatin, bevacizumab
- Where
- United States
- Volunteers
- 842 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer Metastatic
Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLC
This is an open -label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Vactosertib in Combination with durvalumab in patients advanced NSCLC who progressed following…
- Trial name
- NCT03732274
- Testing
- TEW-7197
- Where
- 4 sites in South Korea
- Volunteers
- 60 people
- Sponsor
- MedPacto, Inc.
Carcinoma, Non-Small-Cell Lung
Randomized Phase 2 Study of 3 Therapeutic Modalities in PS 2/3 Patients With NSCLC Stage IIIB/IV
Patients presenting a deterioration of the general state (performance status [PS] 2-3), constitute a population which needs an adapted treatment.
- Trial name
- NCT00198393
- Testing
- Gefitinib, gemcitabine, Docetaxel
- Where
- 2 sites in France
- Volunteers
- 126 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Metastatic Non-Small Lung Cell Cancer, Recurrent Non-Small Lung Cell Cancer
Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade
This phase 2 trial will evaluate the safety and efficacy of combining immunotherapy with a PD-1 checkpoint inhibitor (Pembrolizumab), an anti-VEGF receptor (Ramucirumab), and a taxane chemotherapy (Docetaxel) in treating patients…
- Conditions
- Metastatic Non-Small Lung Cell Cancer, Recurrent Non-Small Lung Cell Cancer, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8
- Trial name
- DoceRamPem (NCT04340882)
- Testing
- Docetaxel, Pembrolizumab, Ramucirumab
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Emory University
NSCLC Stage IV, Brain Metastases
Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Metastasis
Non-small cell lung cancer (NSCLC), the most prevalent form of lung cancer, has a significant risk of brain metastasis (BM). Historically, the median overall survival for advanced NSCLC patients with BM was under six months with…
- Trial name
- NCT06501391
- Testing
- PD-L1/PD-1 inhibitor and chemotherapy, SRT or WBRT
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Fudan University
Metastatic Lung Cancer
LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG Cancer. LIBERTY LUNG
Patient with histologically proven NSCLC in a metastatic stage, treatment naïve and eligible for first-line treatment with immune checkpoint inhibitor. Combination with chemotherapy is possible.
- Trial name
- LIBERTYLUNG (NCT04790682)
- Testing
- assessment of the predictive value of ctDNA level of the prominent mutant allele variation between baseline and week 6, on response to treatment according to RECIST 1.1 criteria.
- Where
- 3 sites in France
- Volunteers
- 300 people
- Sponsor
- Institut Curie
Non-Small Cell Lung Carcinoma (NSCLC)
A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.
This Phase III, randomized, double-blind study compares the efficacy and safety of SCTB14 versus pembrolizumab as first-line treatment in patients with driver gene-negative, TPS ≥10% locally advanced or metastatic non-small cell…
- Trial name
- NCT07362459
- Testing
- SCTB14, Pembrolizumab
- Where
- China
- Volunteers
- 246 people
- Sponsor
- Sinocelltech Ltd.
Stage IV NSCLC
Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC
Veterans with advanced lung cancer may benefit from recent advances in technologies that is designed to change the activities of their own white blood cells and help kill tumors.
- Trial name
- HAITEN-ICI (NCT06064279)
- Testing
- Poly ICLC, IVIG
- Where
- United States
- Sponsor
- VA Office of Research and Development